Development and validation of a scale to measure disease-related symptoms of kidney cancer
Development and validation of a scale to measure disease-related symptoms of kidney cancer
复制标题
DOI：
10.1111/j.1524-4733.2007.00183.x
复制
发表时间：
2007-07-01
期刊：
影响因子：
4.5
通讯作者：
Bro, William P.
中科院分区：
文献类型：
--
作者：
Cella, David;Yount, Susan;Bro, William P.
目的：使用患者和专家提供者的输入，我们以前开发了一个15项指数，用于治疗晚期肾癌的最重要症状和关注点，癌症治疗功能评估-肾脏症状指数（FKSI）。这15个问题是疾病相关症状和治疗相关副作用的混合物。因此，可能很难为定义为这15个最重要问题之和的分数分配信息标签。由于治疗晚期肾癌的主要目标之一是缓解疾病相关症状，因此我们开始从15种症状中区分出主要归因于肾癌本身而不是其治疗的症状，并评估这种缩写的FKSI-疾病相关症状方法：总结了18位经验丰富的临床专家的调查结果，以将DRS与其他可能归因于治疗副作用的问题分开。这九项FKSI-DRS，然后验证了141人的样本与kidney cancer.Results：FKSI-DRS是可靠的（内部一致性范围= 0.75-0.78;重测信度组内相关= 0.85），有效的，分离组的性能状态和患者自己的全球变化评级。在FKSI-DRS的可能最小的重要差异是在2-3 points.Conclusions的范围内：FKSI-DRS是一个可靠的，有效的，和响应的最重要的症状与晚期肾癌相关的简短指数。
Objectives: Using patient and expert provider input, we previously developed a 15-item index of the most important symptoms and concerns of people being treated for advanced kidney cancer, the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). These 15 concerns are a mixture of disease-related symptoms and treatment-related side effects. As a result, it may be difficult to assign an informative label to the score defined as the summation of these 15 most important concerns. Because one of the primary goals of treating advanced kidney cancer is the relief of disease-related symptoms, we set out to differentiate from the list of 15 symptoms those that are predominantly attributable to kidney cancer itself rather than its treatment, and to evaluate this abbreviated FKSI-Disease-Related Symptoms (FKSI-DRS).Methods: Survey results from 18 experienced clinical experts were summarized to separate DRS from other concerns more arguably attributable to treatment side effects. This nine-item FKSI-DRS was then validated on a sample of 141 people with kidney cancer.Results: The FKSI-DRS is reliable (internal consistency range = 0.75-0.78; test-retest reliability intraclass correlation = 0.85), and valid, separating groups by performance status and the patient's own global rating of change. The likely minimally important difference in the FKSI-DRS is in the range of 2-3 points.Conclusions: The FKSI-DRS is a reliable, valid, and responsive brief index of the most important symptoms associated with advanced kidney cancer.